Clinical Trial Update: Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring differences in gut microbiota and metabolomic profiles between rifaximin responders and non-responders in diarrhea-predominant ir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Irritable Bowel Syndrome With Diarrhea | Phase 4 | Status: COMPLETED